SG11201803810XA - 1,3,4-thiadiazole compounds and their use in treating cancer - Google Patents

1,3,4-thiadiazole compounds and their use in treating cancer

Info

Publication number
SG11201803810XA
SG11201803810XA SG11201803810XA SG11201803810XA SG11201803810XA SG 11201803810X A SG11201803810X A SG 11201803810XA SG 11201803810X A SG11201803810X A SG 11201803810XA SG 11201803810X A SG11201803810X A SG 11201803810XA SG 11201803810X A SG11201803810X A SG 11201803810XA
Authority
SG
Singapore
Prior art keywords
cambridge
international
methoxy
astrazeneca
building
Prior art date
Application number
SG11201803810XA
Other languages
English (en)
Inventor
Maurice Finlay
Johannes Nissink
Mark Charles
Original Assignee
Astrazeneca Ab
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Cancer Research Tech Ltd filed Critical Astrazeneca Ab
Publication of SG11201803810XA publication Critical patent/SG11201803810XA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SG11201803810XA 2015-11-30 2016-11-30 1,3,4-thiadiazole compounds and their use in treating cancer SG11201803810XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562260789P 2015-11-30 2015-11-30
PCT/EP2016/079250 WO2017093299A1 (en) 2015-11-30 2016-11-30 1,3,4-thiadiazole compounds and their use in treating cancer

Publications (1)

Publication Number Publication Date
SG11201803810XA true SG11201803810XA (en) 2018-06-28

Family

ID=57485461

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201803810XA SG11201803810XA (en) 2015-11-30 2016-11-30 1,3,4-thiadiazole compounds and their use in treating cancer

Country Status (23)

Country Link
US (3) US10323028B2 (de)
EP (1) EP3383873B1 (de)
JP (1) JP6999550B2 (de)
KR (1) KR20180083942A (de)
CN (1) CN108349966B (de)
AR (1) AR106874A1 (de)
AU (1) AU2016363718B2 (de)
BR (1) BR112018010806A2 (de)
CA (1) CA3005495C (de)
CL (1) CL2018001407A1 (de)
CO (1) CO2018006928A2 (de)
EA (1) EA201891241A1 (de)
ES (1) ES2914333T3 (de)
IL (1) IL259510A (de)
MX (1) MX2018006532A (de)
NI (1) NI201800064A (de)
PH (1) PH12018501131A1 (de)
RU (1) RU2018123714A (de)
SG (1) SG11201803810XA (de)
SV (1) SV2018005702A (de)
TN (1) TN2018000127A1 (de)
TW (1) TW201733587A (de)
WO (1) WO2017093299A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
TW201733587A (zh) 2015-11-30 2017-10-01 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
US9938265B2 (en) 2015-11-30 2018-04-10 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
WO2018228435A1 (zh) * 2017-06-13 2018-12-20 南京明德新药研发股份有限公司 作为gls1抑制剂的化合物
AU2019363115B2 (en) * 2018-10-16 2021-12-09 Medshine Discovery Inc. Thiadiazole derivative and uses thereof as a GLS1 inhibitor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451828B1 (en) * 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
BR112014012129A8 (pt) 2011-11-21 2017-06-20 Calithera Biosciences Inc inibidores heterocíclicos de glutaminase
KR102220175B1 (ko) * 2012-11-16 2021-02-24 칼리테라 바이오사이언시즈, 인코포레이티드 헤테로사이클릭 글루타미나아제 억제제
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
EP3092236B1 (de) 2014-01-06 2020-08-26 Rhizen Pharmaceuticals S.A. Neuartige glutaminaseinhibitoren
US20150258082A1 (en) * 2014-03-14 2015-09-17 Francesco Parlati Combination therapy with glutaminase inhibitors
GB201409624D0 (en) 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
TW201733587A (zh) 2015-11-30 2017-10-01 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
US9938265B2 (en) * 2015-11-30 2018-04-10 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
US10040789B2 (en) 2015-11-30 2018-08-07 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer

Also Published As

Publication number Publication date
PH12018501131A1 (en) 2019-01-21
US20210246131A1 (en) 2021-08-12
TW201733587A (zh) 2017-10-01
US10323028B2 (en) 2019-06-18
RU2018123714A (ru) 2020-01-09
JP2018535986A (ja) 2018-12-06
NI201800064A (es) 2018-10-18
CO2018006928A2 (es) 2018-10-10
KR20180083942A (ko) 2018-07-23
JP6999550B2 (ja) 2022-02-10
AU2016363718B2 (en) 2019-11-14
WO2017093299A1 (en) 2017-06-08
US20190389853A1 (en) 2019-12-26
ES2914333T3 (es) 2022-06-09
CN108349966B (zh) 2022-02-15
US20170152255A1 (en) 2017-06-01
CL2018001407A1 (es) 2018-10-12
TN2018000127A1 (en) 2019-10-04
MX2018006532A (es) 2019-05-15
CN108349966A (zh) 2018-07-31
EP3383873A1 (de) 2018-10-10
BR112018010806A2 (pt) 2018-11-27
AR106874A1 (es) 2018-02-28
US10981904B2 (en) 2021-04-20
AU2016363718A1 (en) 2018-07-12
CA3005495C (en) 2023-12-12
US11753405B2 (en) 2023-09-12
SV2018005702A (es) 2018-11-27
EA201891241A1 (ru) 2019-01-31
IL259510A (en) 2018-07-31
EP3383873B1 (de) 2022-03-09
CA3005495A1 (en) 2017-06-08

Similar Documents

Publication Publication Date Title
SG11201803810XA (en) 1,3,4-thiadiazole compounds and their use in treating cancer
SG11201900135YA (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
SG11201903487SA (en) PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF
SG11201804098TA (en) Purinones as ubiquitin-specific protease 1 inhibitors
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201804384UA (en) Geometric configurations for gastric residence systems
SG11201804915RA (en) Methods for treating huntington's disease
SG11201908532UA (en) Macrocyclic compounds as ros1 kinase inhibitors
SG11201804443UA (en) Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
SG11201808990QA (en) Compositions for topical application of compounds
SG11201804132UA (en) Eif4-a-inhibiting compounds and methods related thereto
SG11201908598PA (en) Compounds useful in the treatment or prevention of a prmt5-mediated disorder
CA2859619C (en) Bromodomain inhibitors
SG11201803864YA (en) Carbon composites
SG11201806853VA (en) Abstracted graphs from social relationship graph
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201804712PA (en) Biofuel
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201901873PA (en) Tablet compositions
SG11201901689YA (en) Compounds for treating diseases associated with a mitochondrial dysfonction
SG11201408641UA (en) Phenoxyethyl piperidine compounds
SG11201804587QA (en) Isoindole compounds
SG11201810934TA (en) Microparticles comprising a sulphur-containing compound
SG11201811380RA (en) Chelate compounds
SG11201803808VA (en) 1,3,4-thiadiazole compounds and their use in treating cancer